Phase III Studies

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Condition: Carcinoid Syndrome
ClinicalTrials.gov Identifier: NCT00774930

Octreotide and Interferon alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Condition: Advanced Neuroendocrine Carcinoma
ClinicalTrials.gov Identifier: NCT00569127

Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Conditions: Carcinoid Tumor;
ClinicalTrials.gov Identifier: NCT00690430

Study of Lanreotide Autogel in Non-Functioning Entero-Pancreatic Endocrine Tumours
Conditions: Endocrine Tumors;
ClinicalTrials.gov Identifier: NCT00353496

Phase II Studies

A Combination Study to Determine the Safety and Efficacy of Panzem NCD
With Avastin in Metastatic Carcinoid Tumors
Condition: Carcinoid Tumor
ClinicalTrials.gov Identifier: NCT00328497

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract
Condition: Neoplasms
ClinicalTrials.gov Identifier: NCT00448136

AMG 706 in Treating Patients With Low-Grade Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
ClinicalTrials.gov Identifier: NCT00427349

Avastin (Bevacizumab) and RAD 001 (Everolimus)in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcininoma
ClinicalTrials.gov Identifier: NCT00607113

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions: Cervical Cancer; Gastrointestinal Carcinoid Tumor; Lung Cancer; Sarcoma; Unspecified Adult Solid Tumor; Protocol Specific
ClinicalTrials.gov Identifier: NCT00346385

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Condition: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor
ClinicalTrials.gov Identifier: NCT00602082

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Condition: Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00610129

Combination Chemotherapy and Bevacizumab in Treating Patients With
Advanced Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Lung Cancer;
Neoplastic Syndrome; Neuroendocrine Carcinoma of the Skin
ClinicalTrials.gov Identifier: NCT00227617

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00326469

Lithium for Low-Grade Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor
ClinicalTrials.gov Identifier: NCT00501540

Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Lung Cancer;
Multiple Endocrine Neoplasia 1 and 2 (men1, men2); Neoplastic Syndrome
ClinicalTrials.gov Identifier: NCT00454363

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable
Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00398320

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
Conditions: Neuroendocrine Tumor; Islet Cell Tumor
ClinicalTrials.gov Identifier: NCT00434109

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors; Gastrointestinal Carcinoid Tumor;
Islet Cell Tumor; Pheochromocytoma; Sarcoma;
ClinicalTrials.gov Identifier: NCT00049023

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00442533

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Condition: Metastatic Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00590343

Safety Study of Seneca Valley Virus in Patients With Slolid Tumors With Neuroendocrine Features
Condition: Carcinoid; Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00314925

The Safety and Efficacy of CPTK 787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00627198